Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 5729 - 5736 of 12143 results
Proposed changes to Medicare Advantage audits could put insurers on the hook for billions
October 29, 2018| News
Federal Circuit Denies RPX’s Request for en banc Review in Applications in Internet Time v. RPX
October 26, 2018| Blog| Viewpoint
OIG Publishes Study on Claim and Payment Denials by Medicare Advantage Organizations
October 26, 2018| Blog| Viewpoint
Six Things to Know About the New Section 1332 Waiver Guidance
October 25, 2018| Blog| Viewpoint
NYC Employers Must Engage in "Cooperative Dialogue" on Accommodation Requests
October 25, 2018| Blog| Viewpoint
Strategies to Unlock AI's Potential in Health Care, Part 3: HIPAA and Other Privacy Considerations
October 25, 2018| Blog| Viewpoint
What to Do When Your New Home Is a Lemon
October 25, 2018| News
Fall 2018 Agency Rule List & FDA Device Center Guidance Priorities
October 24, 2018| Blog| Viewpoint
News & Press Releases
Mintz Advises Point72 and Tsunami Express Car Wash in Acquisition of 53 Car Wash Locations from Whistle Express Car Wash
September 16, 2025
Mintz advised Point72 and Tsunami Express Car Wash, its portfolio company, in Tsunami’s acquisition of 53 car wash locations from Whistle Express Car Wash, which is owned by affiliates of Oaktree Capital Management.
Mintz Advises Charlesbank Capital Partners on Acquisition of Q6 Cyber
September 15, 2025
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025
Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”
Events
Podcasts
Mintz On Air: Practical Policies – DEI Developments: The Proxy Problem
September 16, 2025| Podcast|
Mintz On Air: Practical Policies – Disparage Me Not
August 26, 2025| Podcast|
Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|